INTRODUCTION
The highly complex cellular regulatory networks and their interactions with small molecules (A small molecule is a molecule of relatively low weight, perhaps less than 100 atoms. It is the opposite of a macromolecule, such as a protein or DNA.) present challenges to our mechanistic understanding of drug action. Deeper insights into the fundamental mechanisms of cellular functions and pathway regulations are likely to be critical for the development of rational approaches directed at the identification of molecular targets and candidate inhibitors. While the antitumor activity of current anticancer drugs is reflected in cell killing, mechanism-based studies attempt to specifically associate a drug's effect to one or many cellular regulation mechanisms. 1 Individual protein targets of a small molecule may be involved in diverse cellular processes, some or all of which could contribute to the killing potential of a compound. Furthermore, environmental factors such as temperature, radiation, hypoxia, nutrients, as well as drugs stimulate an adaptive sensory and signaling machinery of the cell, and therefore may influence drug sensitivity, cell survival, and apoptosis. It is thus relevant to pursue a global and in-depth vision of the general regulatory circuits of cellular functions when attempting to better understand a compound's mechanism of action (MOA).
One general approach to identify target-specific agents as a basis for understanding a drug's MOA is to relate gene expression patterns measured across a diverse set of tumor cell models to drug-induced chemosensitivity of these same cells. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Previous efforts using this strategy have focused mainly on finding causes of drug resistance. [2] [3] [4] 11, 17, 18 Gene expression signatures have also been used as surrogate markers of cellular states, for example, to identify agents that induce the differentiation of acute myeloid leukemia cells. 19 However, nearly all of these investigations have been based on single gene expression-drug response relationships, whereas complex interactions between a drug and highly interconnected biological networks may not be reflected solely by the state of any one gene. Moreover, quantitative assessments that associate significant correlations between gene expression levels and drug sensitivity as a basis for validating a biologically significant connection are not yet a standard practice.
Previously, we examined correlative associations between gene expression coherence within predefined pathways and functionally related gene groups. 20 Our goals in the present study are to extend this work by incorporating the existing biological pathway and gene expression information with drug chemosensitivity data, and apply these findings toward the deconvolution of a drug's MOA. Our analysis proposes a novel strategy for examining entire pathways according to each pathway's component gene expressions, and establishing a quantitative measure of biological significance represented by correlations in gene expression and drug response patterns. The strongest pathway-drug associations are used to validate or gain a better understanding of a drug's MOA, and, subsequently, to propose agents that can perturb specific pathways. Our analysis focuses on the microarray constitutive gene expression data measured across the NCI's 60-tumor cell screen (NCI 60 ), and cytotoxicity data generated in the same cell lines from in vitro anticancer drug screening. These immortalized tumor cell lines reflect diverse cell lineages as they are derived from lung, renal, colorectal, ovarian, breast, prostate, central nervous system, melanoma, and hematological malignancies. Since its inception in 1990, cytotoxicity measures for over 40 000 compounds have been obtained that are publicly available. We have organized, specifically, the tumor cell growth inhibition (GI 50 ) data into self-organizing maps (SOMs). 21 GI 50 growth patterns have been found to be an informationrich resource for establishing a compound's MOA. 16, [22] [23] [24] SOM clustering of the GI 50 data segregates compounds into nine major response categories: mitosis (M), membrane function (N), nucleic acid metabolism (S), metabolic stress and cell survival (Q), kinases/phosphatases and oxidative stress (P), and four unexplored regions R, F, J, and V. 16, 23, 24 Each of these regions is further divided into a total of 80 clades (a clade is a group of clusters (nodes) that share similar cytotoxic responses) (subregions: M 1 -M 8 , N 1 -N 13 , P 1 -P 8 , Q 1 -Q 7 , R 1 -R 7 , S 1 -S 13 , F 1 -F 8 , J 1 -J 8 , V 1 -V 8 ) (Figure 1 ). The current SOM extends our previously published analysis to include the existing complement of newly screened compounds. 23 Gene expression patterns across the NCI 60 can be organized in terms of predefined pathways or functional Figure 1 Cytotoxicity measurements for nearly 30 000 small molecules screened against the NCI's tumor cell panel (NCI 60 ) were clustered into 1350 groups or nodes using an SOM. 23 Each cluster is represented by a hexagon and neighboring clusters identify compounds with similar cytotoxicity responses. These nodes are separated into nine major response categories (regions): mitosis (M), membrane function (N), nucleic acid metabolism (S), metabolic stress and cell survival (Q), kinases/phosphatases and oxidative stress (P), and four unexplored regions R, F, J, and V. Each of these regions is colored differently and further divided into a total of 80 clades (a clade is a group of clusters that share similar cytotoxic responses) (subregions: M 1 -M 8 , N 1 -N 13 , P 1 -P 8 , Q 1 -Q 7 , R 1 -R 7 , S 1 -S 13 , F 1 ÀF 8 , J 1 -J 8 , V 1 -V 8 ), shown here by the black boundary lines.
Pathway gene expressions and cellular growth inhibition categories annotated by the Kyoto Encyclopedia of Genes and Genomes (KEGG), BioCarta, and Gene Ontology (GO). These widely used, publicly available gene annotations will be employed to link pathways to drug responses through correlations between pathway gene expression patterns and drug GI 50 response profiles clustered in SOM clades. Implicit in this design is the assumption that cytotoxicity profiles most strongly associated with gene expression profiles for genes within a defined pathway are valid indications of a test compound perturbing a specific pathway; conversely, the gene products in the pathway would play major roles in dictating the cytotoxic activity of the compound. Our approach associates drug responses in each clade with subsets of pathways. These subsets of pathways can then be clustered based on their positions on the GI 50 SOM. Pathway gene expression coherence levels 20 will also be discussed in terms of targetability. We will establish a quantitative measure of the degree to which a significant pathway-drug response correlation represents a biologically significant association via comparison to known drug-target relationships. Assignment of putative MOAs for agents clustered in each SOM response region are then postulated to involve pathways that can be significantly correlated with these agents.
RESULTS
An important challenge to associating gene expression in the context of biological pathways involves the formulation of effective strategies to relate drug action to precise molecular targets. Since the practical goal of our strategy is to utilize drug-gene-pathway relationships to propose novel drug targets or target-specific drugs, the biological response of a molecular activity, such as a GI 50 profile, represents a crude, albeit relevant, readout of the drug's interaction within a cellular milieu. For example, if a drug interacts with one gene product, the entire pathway or pathways having this gene may be disturbed, and a direct correlation may not be apparent. Alternatively, the consequence of a drug action may be revealed by correlations of the drug response to other gene expressions within the pathways containing the putative target. Cases where single drug-gene correlations are not directly apparent may be revealed by this broader examination of related genes within a pathway.
Finding Pathways Correlated with Specific Drug Responses:
Mapping Pathways to GI 50 SOM Clades A hallmark of targeted molecular therapies is over-expression of the drug's molecular target. Strong support for this rationale can be found within the NCI 60 screen, as evidenced by positive correlations between gene expressions of the proteasome and heat shock proteins to Velcade s and geldanamycin, respectively. 16 Extending these cytotoxicitygene expression correlations to pathways is an attempt to establish a pathway-centric perspective to a drug's MOA. Instead of examining each individual drug-gene correlation, correlations between the GI 50 SOM clades (clusters of drugs with similar GI 50 profiles) and pathways as collections of genes are evaluated as a more general approach. For each pathway, correlations with GI 50 clades are compared between genes 'on a pathway' with genes 'off a pathway', and the Kruskal-Wallis H statistic is calculated (see Data and methods section for computation details). A pathway is considered significantly correlated with the drug clade if H40 and Po0.05. Our underlying reasoning takes advantage of clustering results that partition response data into a smaller number of groups, and at the same time reduces the computational requirements. With this approach, the B30 000 drug GI 50 response profiles are condensed to 80 SOM clades (response regions), and 5K genes are condensed to hundreds of pathways.
Using this method, each pathway in KEGG, BioCarta, and each GO term are mapped onto the GI 50 SOM, where each clade has an H-score, representing the strength of correlation between the pathway and the compounds in that clade. The most significantly and specifically correlated pathways are proposed as the most likely targets of the drugs within a clade. Figure 2 (left panel) shows the mapping of the 111 KEGG pathways on the GI 50 SOM, where each horizontal band is a pathway, each vertical band is a SOM clade, and each small square is colored according to the correlation strength of that pathway's gene expressions with that clade's GI 50 responses. A reddish color indicates that the clade's GI 50 patterns correlate stronger with the gene expressions in the pathway compared to expressions for genes not in the pathway, a bluish color indicates the opposite, and a yellowgreenish color indicates that there is no significant difference between the 'on' and 'off' pathway gene correlation strengths. The right panel of Figure 2 shows two examples of pathways mapped on the GI 50 SOM, the MAPK signaling pathway (top) and oxidative phosphorylation (bottom). These two maps are also colored according to the pathwayclade correlation strength in a similar manner. Oxidative phosphorylation is one of the most cohesive KEGG pathways and it shows strong significant correlations with the agents in a few clades in the R-region (R 5 , P ¼ 1.01 Â 10 À4 and R 4 , P ¼ 1.12 Â 10 À3 ), V-region (V 6, P ¼ 1.33 Â 10 À6 and V 3 , P ¼ 1.72 Â 10 À3 ), and N-region (N 6, P ¼ 4.26 Â 10 À3 and N 13 , P ¼ 0.012). Noteworthy is that many known inhibitors, including the acetogenins, [25] [26] [27] of mitochondrial complex I, which plays a critical role in the oxidative phosphorylation pathway, are mostly clustered in R 5 and R 4 . The MAPK signaling pathway, on the other hand, is one of the least cohesive KEGG pathways. It correlates the strongest with parts of the N-region (N 5 , N 7 , N 8 ), but none is significant; its strongest correlation only has an H-score of 3.26 (P ¼ 0.07).
Hierarchical clustering of the pathway-clade H-score matrix further segregates the 111 KEGG pathways into 24 clusters (Figure 2 , left panel). These clusters can be used to assess whether pathways involved in similar biological processes share similar correlation patterns. KEGG groups pathways into five general categories ( Figure 3 , top panel), Cellular Processes, Environmental Information Processing, Genetic Information Processing, Human Diseases, and Metabolism. These groups are further divided into 22 subcategories (Figure 3 , bottom panel). Figure 3 shows the composition of each of the 24 pathway clusters, shown in the same order as the dendrogram in Figure 2 , ie, adjacent clusters have similar correlation patterns, according to the five general categories (top panel) and the 22 subcategories (bottom panel). Pathways belonging to the same category generally cluster together, that is, they share similar GI 50 clade correlation patterns. The 81 metabolic pathways are scattered across all 24 clusters; however, 15 of these clusters are composed solely of metabolic pathways ( Figure 3 , top panel). Furthermore, cluster #2 is composed solely of pathways involved in lipid metabolism, which are most correlated with compounds in SOM regions F and J ( Figure  2 , left panel); cluster #5 solely of amino acid metabolism, which are most correlated with the F-region; cluster #7 is composed of two other amino acid metabolism pathways, which are most correlated with regions J and Q; cluster #11 is composed solely of carbohydrate metabolism pathways, which are most correlated with the N-region; cluster #20 is composed solely of energy metabolism pathways, which are most correlated with regions R and V; and cluster #24 is composed solely of pathways responsible for glycan biosynthesis and metabolism, which are most correlated with the Q-region. Cluster #15 contains five of the eight human diseases pathways, which are most correlated with regions V, P, and M. Four of the eight pathways involved in genetic information processing are also grouped together in cluster #15, which is most correlated with regions N, S, V, and M. Five of the six signal transduction pathways, which is the major component of environmental information proces- The dendrogram generated from the hierarchical clustering of pathways based on the H-scores is shown on the left side of the figure and the 111 pathways are arranged in the order as they appear in the dendrogram such that neighboring pathways have similar GI 50 response associations. The right panel of the figure shows the mappings of the MAPK signaling pathway (top), a pathway with genes not coherently expressed, and the oxidative phosphorylation pathway (bottom), one of the most cohesive pathways, to the GI 50 SOM. Each of these two pathway-to-GI 50 maps is colored according to its corresponding row in the H-score matrix.
Pathway gene expressions and cellular growth inhibition sing, fall into one cluster, cluster #9. Collectively, signal transduction pathways are among the least cohesive pathways; their correlations with the GI 50 SOM regions are generally diffuse, lacking assignment to any one clade or region in GI 50 response space. Conversely, this might also imply that it will be difficult to find drugs that target specifically to one of these signaling pathways.
Looking at the KEGG pathway-GI 50 SOM clade correlation matrix (Figure 4 ), one can also see that some pathways are significantly correlated with many drug clades, while some are correlated with very few. These KEGG pathways are correlated, on average, with 3.5 drug clades (4.4%). The top histogram in Figure 4 shows the number of pathways significantly correlated with each GI 50 SOM clade, which represent the biological processes that those drug agents are potentially perturbing. On average, each clade is correlated with B5 KEGG pathways (4.4%). The more the pathways correlated with a drug clade, the less specific the drugs in the clade may be, and vice versa. Three clades (shown as green bars in the histogram), P 8 (limonene and pinene degradation), J 1 (ribosome), and S 1 (ribosome), are only correlated with one pathway each, and nine other clades (shown as yellow bars in the histogram) are each correlated with two pathways. These potentially contain drugs with specific targets. On the other hand, 11 of the 80 drug clades (shown as orange bars in the histogram) each correlate with more than eight pathways (B7%), and Q 5 seems to be the most promiscuous drug clade having more than 10 significantly correlated pathways, seven of which are involved in glycan biosynthesis and metabolism. Overall, as illustrated in Figures 2 and 4 , the different pathways appear to be fairly evenly spread over all SOM regions. This is consistent with the fact that the collection of screened compounds shows a wide spectrum of responses. Drug clades and their correlated pathways will not be examined individually here, but drugpathway relationships will be discussed in greater detail in the following sections.
Validation of Pathway-GI 50 SOM Clade Correlations
We have shown that some pathways have significant correlations with drug GI 50 response profiles; however, a natural question to ask is that if, or to what degree, a significant correlation derived for a pathway and a drug clade represents a real biological connection between the drugs in that clade and the pathway. To answer this question, protein products for our measured set of genes that are known to have small-molecule inhibitors, derived either from the literature or from known protein-ligand complexes with determined structures, are used as representative cases of established gene/pathway-drug connections; and the strengths of the correlations between these agents and their known target pathways are examined. A connection between a small-molecule drug and a pathway is assumed to exist if the drug has been cited in the literature as a known inhibitor of at least one of the gene products in the pathway (B100 000 unique drug-gene pairs), or if the drug has a structural match, at Tanimoto 28,29 0.90 or above, to a ligand of a protein (retrieved from the Protein Data Bank (PDB) 30 ) whose corresponding gene (determined by sequence alignment at expectation value p10 À20 ) is a member of the pathway (B1000 drug-gene pairs). For a particular pathway-drug pair, the pathway-clade H-score of the clade where the drug is located is used as their correlation score. Each drug-pathway pair is assigned to one of four categories at various significance levels (P-values): true positive (TP), false positive (FP), false negative (FN), and true negative (TN), according to the following decision table (Table 1 ). The number of drugpathway pairs within each category is counted.
Out of all unique drug-pathway combinations, the protein-ligand data set contains between 1-6% and the literature-derived known inhibitor-target data set contains B15% of drug-pathway pairs that have literature-established connections, depending on the pathway system used. Initially, we determined whether a stronger drug-pathway correlation signifies a more likely 'true hit', that is, the drug is a true inhibitor of the pathway, or the drug and the pathway have an established connection. The property of interest is then the ability of using the correlation to select 'true positives', called the 'positive predictive value' (defined as TP/(TP þ FP)), which is an important index of the actual performance of a test. The positive predictive value is found to increase with increasing correlation significance level, as shown in Figure 5 (a), obtained using the known inhibitortarget data set. (Same calculations are also done using the protein-ligand data set and similar trends are observed.) These observations partly confirm the hypothesis that the more significant the correlation between a drug and a pathway, the more likely that the drug is a true inhibitor of that pathway. At significance level PB10 À5 , the TP/(TP þ FP) ratio is about 0.25 (increased from 0.2 at PB10 À2 ), which means that, in approximately one out of four pathway-drug pairs found to be significantly correlated at this level, the Pathway gene expressions and cellular growth inhibition drug appears somewhere in the literature as being a known inhibitor of, or having a direct or indirect connection with, some gene products in that pathway. This confidence level establishes a quantitative reference for using our approach to find drugs that target certain biological pathways with the data set we have at hand. Two metrics commonly used in clinical studies to test the accuracy of a certain diagnostic test are 'sensitivity' and 'specificity'. Sensitivity, defined as the proportion of subjects with the disease who have a positive test (TP/(TP þ FN)), describes how well a diagnostic test identifies those people with the disease, and, in our case, how well the correlation identifies the drug-pathway pairs with true connections.
Similarly, specificity is defined as the proportion of subjects without the disease who have a negative test (TN/(TN þ FP)), and, in our case, describes how well the correlation identifies the drug-pathway pairs without a known connection. In general, a good testing procedure is characterized by high sensitivity and specificity, whereas, in reality, when the sensitivity is very high, the specificity tends to be low. We have observed that, as the correlation strength increases, specificity increases while sensitivity decreases. This is because when correlation significance levels are higher, there are fewer correlated drug-pathway pairs (which means lower sensitivity), even though the likelihood of them being 'true hits' is better (which means higher specificity). A FP) ) against correlation significance (Àlog(P)) for the KEGG pathways and GO terms. At P ¼ 1, the PPV represents the total fraction (15%) of pathway-drug pairs with literature established connections present in the data set. At P ¼ 10 À5 , about 25% of the correlated pathway-drug pairs have literature-established connection. (b) The ROC curves for the KEGG pathways and GO terms. The area below the ROC curve and above the diagonal is indicative of the quality of the method used to generate the curve. Both plots are generated by counting the fractions of pathway-drug pairs assigned to each of the four categories: TP, FP, FN, and TN according to Table 1 at various correlation significance levels as indicated by the Kruskal-Wallis test.
Pathway gene expressions and cellular growth inhibition receiver operating characteristic (ROC) curve, which is a plot of sensitivity versus 1Àspecificity, is commonly used as an efficient way to display the relationship between sensitivity and specificity. 31 The preferred test yields the greatest number of true positives with the least number of false positives, resulting in a ROC curve that tends upwards while moving from right to left. Figure 5(b) shows the ROC curves derived from our drug-pathway correlation method using the KEGG and GO annotations. These results exhibit the desired features of a valid testing procedure.
Nevertheless, one might still argue that the known inhibitor-target connections appearing in the literature could be random and the observed trend of greater predictive value with higher correlation significance could happen by chance. To check whether this is true, randomization procedures are employed to estimate the probability of finding this trend, with the observed magnitude, by chance. The same set of drugs and pathways are used in the procedure, but drugs are assigned randomly as inhibitors of each pathway, while the percentage of drug-pathway pairs with 'known' connections is controlled to approximate the percentage in the real (nonrandomized) calculations (approximately 15%). For instance, if there are a total of n unique drug-pathway pairs and in m of them the drugs are mentioned in the literature as known inhibitors of their partner pathways, then in the random simulations m unique pairs will be randomly picked from the n drug-pathway pairs and labeled as having 'known' connections. The drugpathway pairs that fall in each of the four categories (TP, FP, TN, FN) are counted and the predictive values are calculated at various significance levels with the randomized drugpathway pairs. This procedure is repeated 1000 times and 1000 profiles of TP/(TP þ FP) at various P-values are obtained. Figure 6 shows the TP/(TP þ FP) profile calculated using the GO system with real drug-pathway connections (dark solid curve on top), plotted together with the average TP/(TP þ FP) profile of the thousand profiles generated using randomly assigned drug-pathway connections. The random predictive values show no change with increasing significance levels (decreasing P-values), except for random fluctuations above and below the starting predictive value at P ¼ 1 (Àlog(P) ¼ 0). Based on the distribution of the 1000 random fluctuation amplitudes, the chance probability of getting the observed predictive value is about 10 À30 (t-test). This rejects, with nearly 100% confidence, the hypothesis that the observed trends could happen by random chance.
The mapping of a pathway to a GI 50 clade via the existence of a significant correlation (Po0.05) with that clade's cytotoxic profiles is therefore considered 'validated' if at least one of the drugs in that clade has established connections, either through ligand-protein relationships or from the literature, with the pathway. Limited by the availability of established known inhibitor-gene product relationships and the availability of gene expression and drug GI 50 data, not all pathways can be 'validated' in this fashion. The validated pathways and their known inhibitors are listed in Tables 2 and 3 Figure 6 Validation of the PPV of the pathway-drug correlation method via comparison to random cases. The top curve is a plot of PPV against -log(P) generated using GO terms, and the bottom three curves are obtained from 1000 randomly generated pathways. In the random case, the average PPV plot (flat line in the middle) does not show any apparent change as correlation significance level (Àlog(P)) increases. The two curves above and below the average plot represent the three-standard-deviation window for random fluctuations. The deviation of the PPV plot generated using GO terms from random is significant (t-test: Po10
À30
). This clearly shows that the increase of PPV with increasing correlation significance can only be observed with vetted gene functional categorization systems, such as pathways.
Pathway gene expressions and cellular growth inhibition Pathway gene expressions and cellular growth inhibition Table 2 lists the pathway-drug connections validated using the protein-ligand data set. The mapping of two KEGG pathways, nine BioCarta pathways, and 22 GO terms is validated. Some of these pathway-drug connections have a well-established mechanistic basis; for example, the NSC drug listed for CSK is staurosporine, which is a well-known kinase inhibitor; the drugs listed for DHFR are methotrexate and its close structural analog; and drugs listed for TOP1 are mostly camptothecin analogs. In other cases, the drugs listed are either known ligands (not necessarily established inhibitors) of a gene product (or a sequence analog of the protein) in a pathway, or their close structural analogs; for example, the NSC drugs listed for HMGCR are close structural analogs of HMG. Table 3 lists the pathway-drug connections validated using the known inhibitor-target data set from the literature. Owing to space limitations, only the validated pathways are listed here and their corresponding genes and drugs can be found in Table IV pathway through other indirect mechanisms. For example, the NSC drugs connected to the GO term DNA topoisomerase (ATP-hydrolyzing) activity through TOP2 include wellknown TOP2 inhibitors such as etoposide, teniposide, razoxane, dexrazoxane, mitindomide, and other drugs, including DNA-damaging agents which may be indirectly linked to TOP2 activity. Geldanamycin, 17-AAG, herbimycin A, and macbecin I and II, among other drugs, are connected to GO terms such as heat shock protein activity, co-chaperonin activity, and protein folding through HSP90. We consider the pathway-drug connections associated with these validated pathways to be more reliable. Nevertheless, one still needs to be aware of the drug-pathway connections that fall into the false-positive or -negative (FP and FN) categories. It will also be interesting to examine the drugs in clades that are significantly correlated with a pathway, but no known biological connection has been established.
Connecting Pathways with GI 50 SOM Response Regions: Putative MOA One of the primary goals of our drug-pathway analysis is to aid in finding and interpreting drug targets and MOA. Using the methods described above, the biological pathways that are potentially perturbed by the drugs in the nine SOM response regions can be postulated. Conversely, each path- For each pathway, the table lists the name of the pathway, the expressed protein of the gene within the pathway where a structure exists as a complex with a small molecule ligand deposited in the PDB, the PDB ID of the protein-ligand complex, the NSC number of the small-molecule compound that is structurally similar to the ligand and has its GI 50 profile determined in the NCI 60 , the Tanimoto score that indicates the structural similarity between the small-molecule compound and the protein ligand (only compounds with Tanimoto scores of at least 0.9 are considered in our analysis), and the significance level of the connection between the pathway and the small-molecule compound (P-value). Pathways labeled with an asterisk have their genes significantly coherently expressed. 20 way may be associated with one or more response regions. A pathway is 'best-mapped' to a specific SOM region if all the following conditions are met: the region contains at least one clade significantly correlated with the pathway (pathway-clade correlation score40 and Po0.05), the region average pathway-clade correlation score is positive, and the region has the highest average pathway-clade correlation score (hit score) or the highest percentage (hit rate) of significant clades among all regions. Table 4 lists the primary and secondary response regions for the KEGG pathways and GO terms when mapped in this fashion (Data for BioCarta pathways can be found in Supplementary Information). Due to space limitations, only the pathway-GI 50 response region associations that have been validated, as described earlier, through either known inhibitor-target or ligand-protein connections, are listed. For GO terms, only the associations with the best mapping scores are shown. Some pathways are associated with more response regions than others, that is, these pathways have significant correlations with many different drug GI 50 profiles, indicating that many different agents can potentially disrupt these pathways. The degree of GI 50 SOM 'coverage' of a pathway is determined by both the gene expression coherence of the pathway, and the overall correlation strength of the genes in the pathway with the GI 50 profiles. On the other hand, the pathways that are associated with a SOM region collectively represent, putatively, the biological processes or molecular targets of the compounds clustered in that region, that is, those that are involved in their MOA. We have previously established the general MOA of the agents in some of these SOM regions: mitosis (M), membrane function and oxidative stress (N), nucleic acid metabolism (S), and metabolic stress and cell survival (Q), oxidative metabolism (R), and kinases/phosphatases and oxidative stress (P), via other methods. 16, 23, 24 The pathway mapping results provide additional support for the annotation of some of the SOM regions: for example, the GO terms mitotic checkpoint, cytokinesis, kinetochore, and cell cycle are associated with the M-region; the GO terms mitochondrial inner membrane (data not shown), response to oxidative stress (data not shown), and oxidoreductase activity are associated with the N-region; the KEGG pathway one carbon pool by folate, the BioCarta granzyme Amediated apoptosis pathway, the GO terms DNA topological change and DNA topoisomerase (ATP-hydrolyzing) activity, are associated with the S-region; the KEGG pathway glutamate metabolism and the GO terms (data not shown) xenobiotic metabolism, cysteine metabolism, and glutathione biosynthesis are associated with the Q-region; the KEGG pathways fatty acid metabolism and oxidative For each pathway, the table lists the name of the pathway, the significance level of the connection between the pathway and its small-molecule inhibitors (P-value), and the number of references where the small molecule is documented as an inhibitor of the product of a gene in the pathway (see Supplementary Information, Table IV, Galactose metabolism N hsa00252
Alanine and aspartate metabolism N hsa00680
Methane metabolism N hsa04350 TGF-beta signaling pathway* N hsa00632
Benzoate degradation via CoA ligation N M Q hsa04070
Phosphatidylinositol signaling system N S hsa00630
Glyoxylate and dicarboxylate metabolism P hsa00720
Reductive carboxylate cycle (CO 2 fixation) P hsa05110
Cholera infection P F M hsa00251
Glutamate metabolism Q hsa00670
One carbon pool by folate Q N S hsa00710
Carbon fixation Q hsa03010 Ribosome* Q R hsa05060
Prion disease Q R hsa04060
Cytokine-cytokine receptor interaction R hsa04510
Integrin-mediated cell adhesion* R hsa05010
Alzheimer's disease R Q hsa05050
Dentatorubropallidoluysian atrophy (DRPLA)* R V M hsa00190
Oxidative phosphorylation* V R N hsa00220
Urea cycle and metabolism of amino groups V hsa00970
Aminoacyl-tRNA biosynthesis* V N M Cytoskeleton organization and biogenesis R P J Pathway gene expressions and cellular growth inhibition phosphorylation and the GO terms NADH dehydrogenase (ubiquinone) activity, NADH dehydrogenase activity, oxidoreductase activity, and mitochondrion are associated with the R-region; and the BioCarta pathways (data not shown) signaling of hepatocyte growth factor receptor, Erk1/Erk2 MAPK signaling pathway, ATM signaling pathway, FAS signaling pathway (CD95), and the GO terms (data not shown) oxidoreductase activity (acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen), cell-cell signaling, and DNA damage response (signal transduction resulting in induction of apoptosis) are associated with the P-region. Moreover, the additional pathways that are associated with each SOM region through this global pathway analysis procedure provide valuable information and new insights into the MOA for similarly clustered drug molecules, especially for the validated pathway-drug connections. Of particular interest are the associations of apoptosis with the M-region, cell adhesion, and immune response signaling pathways with regions N and P, transport with the N-region, Pathway gene expressions and cellular growth inhibition hypoxia and angiogenesis with the P-region, DNA replication, regulation of DNA repair, and translation with the Qregion, and cytoskeleton with the R-region. Finally, the MOA of the agents clustered in the three regions, F, J, and V, can be postulated by examining the pathways associated with these regions: for example, the amino-acid metabolism pathways and the wnt signaling pathway mapped to the Fregion, cell cycle and DNA damage-related pathways mapped to the J-region, and urea cycle and metabolism of amino groups and pyruvate metabolism mapped to the Vregion, which seems for the latter to share pathways with its neighboring regions. In fact, many pathways are shared among different SOM regions and conversely each region is usually associated with multiple pathways. This is expected because any one biological process can be perturbed by many drugs, but to different degrees. The agents that can most effectively disrupt a process could be hypothesized by looking at the most significantly correlated sets. Moreover, each SOM region contains the GI 50 profiles for thousands of compounds; therefore, it is not surprising that multiple processes, even though usually related, are associated with these compounds. To gain more specific information on the MOA of one compound or a small cluster of related compounds, a detailed drug-pathway analysis, as described earlier, is required. The region-wide analysis of biological pathways and drug response, however, provides a global view of biological activities or features shared by large groups of compounds.
DISCUSSION
Our study presents the first in-depth, large-scale analysis of pathway gene expressions in relation to drug activities. One of the important goals of understanding the nature of gene expression regulation and biological pathways is to apply this knowledge to understanding the mechanism by which small drug molecules interfere with the biological system through interactions with gene products and consequently pathways. Drug-gene-pathway relationships may then be utilized to find drug targets or target-specific drugs. We have mapped each pathway in KEGG, BioCarta, and each GO term onto the drug GI 50 SOM based on the strength of correlation between the pathway and the compounds in each GI 50 clade. The most significantly and specifically correlated pathways are intuitively the most likely targets of the drugs within a GI 50 clade. Clustering of the KEGG pathways based on their GI 50 clade correlation patterns shows a higher level of pathway regulation, that is, pathways belonging to the same broader biological process category generally cluster together. This indicates that pathways engaged in the same biological process tend to share similar drug GI 50 correlation patterns, or behave similarly toward drugs, and each group of pathways can be associated with specific SOM regions. As we have established earlier, 20 pathways responsible for vital cellular processes or processes that are related to growth or proliferation, specifically in cancer cells, such as those engaged in genetic information processing, cell cycle, energy metabolism and nucleotide metabolism, are found to have significantly more coherent gene expressions than most signaling and regular metabolic pathways. The cohesive pathways (names labeled with an asterisk in the right panel of Figure 4 and in Tables 2-4) are also found here to have stronger pathway-drug correlations, in general, than noncohesive pathways, since the high level of gene coexpression in cohesive pathways makes it more likely for genes in the pathway to have similar correlation patterns with, or act coherently toward, a drug. This may then imply that cohesive pathways are easier to target, since many drugs seem to be able to significantly disrupt these pathways. Conversely, the correlations of the least cohesive pathways with the GI 50 SOM regions are generally diffuse and not strong or specific to any one clade or region. This may be an indication that it will be hard to find drugs that can target noncohesive pathways, or the relationship between drugs and these pathways are not reflected or easily interpretable by simple gene-drug correlations. Therefore, instead of looking at noncohesive pathways that do not correlate significantly with any drugs, it may be more interesting to examine those noncohesive pathways that can act coherently toward certain drugs; that is, how correlation or interaction with drugs changes their intrinsic cohesiveness. Taking this one step further, in addition to looking at 'drugcoupled' pathway cohesiveness through correlation, valuable information may be obtained by examining 'drugexposed' pathway cohesiveness, that is, to analyze and compare gene expression cohesiveness within a pathway prior to and after drug exposure.
The number of pathways significantly correlated with each GI 50 SOM clade, on the other hand, represents the number of biological processes the drug agents in the clade are potentially perturbing. This number can be used as an indicator of the level of target specificity or promiscuity of these drugs. High pathway correlation promiscuity is indicated for some drugs. Although this may seem undesirable because of multiple targets and thus the potential of detrimental side effects implicated for the drug, this may represent cases where assaulting a single target by the drug can cause multiple intracellular effects, as reflected by correlations with multiple pathways. This, on the other hand, can be deemed as a desirable property of the drug, because it presents the potential of overcoming the insufficiency of single target inhibition caused by the inherent ability of heterogeneous tumor populations to activate alternative or redundant pathways. 32 Based on this premise, drugs with many significantly correlated pathways may warrant further exploration.
However, a general concern regarding the interpretation and application of pathway-gene-drug correlations is whether, or to what degree, a significant correlation derived for a pathway and a drug represents a real connection between the drug and the genes in that pathway. To address this question, we have established the confidence level of this method by evaluating the correlations between a set of small-molecule inhibitors and their known gene targets. These connections have been verified through either the literature or known ligand-protein complexes with determined structures. We have shown that, as the correlation strength between a drug and a pathway increases, it is more likely that a true biological connection exists between the drug and the pathway, and the probability of this happening by pure chance is almost zero. These results can be applied directly in target-specific drug discovery or hypothesizing the MOA of a drug. More specifically, if a GI 50 SOM clade is found significantly correlated with a pathway, we can then test the drugs in the clade against gene targets in that pathway. However, we still cannot seem to avoid the tradeoff between specificity and sensitivity, that is, higher specificity can only be achieved at the expense of lower sensitivity. If we want a smaller chance of a drug-pathway correlation to be a false positive, we would need a higher level of correlation significance between pathway gene expression and cytotoxicity. This would effectively reduce the number of correlated drug-pathway pairs and increase the risk of missing real connections. Conversely, if we want to cover more drugs and pathways, we would have to lower the correlation significance threshold and at the same time increase the chance of getting false positives.
CONCLUSION
We have proposed novel strategies to comprehensively analyze and link pathway gene expressions to drug responses, for the purpose of generating hypotheses about drug targets and mechanisms of action. We have analyzed pathway gene expression patterns and drug GI 50 response profiles derived from the NCI 60 cancer cell panels, and annotated GI 50 response regions on the SOM with pathways defined by KEGG and BioCarta, and functional categories defined by GO, through correlations between pathway gene expression patterns and drug response profiles. Further organization of pathways based on their mapping patterns on the GI 50 SOM reveals that pathways engaged in the same biological process tend to have similar drug responses. We have validated quantitatively the quality of the method relating pathways to drug responses using established drugtarget relationships. These results can be used subsequently to provide potential targets and MOAs for drug molecules. We have, in addition, found that pathways with coherently expressed genes tend to have stronger correlations with drug GI 50 profiles than pathways that do not have coherent gene expressions, whereas some noncohesive pathways can act coherently toward their known inhibitors. These pathways and the genes involved may represent interesting drug targets for further exploration.
DATA AND METHODS

Gene Expression Data
Constitutive gene expression data from Novartis, measured in triplicate across the 60 tumor cell lines using the Affymetrix DNA oligonucleotide microarray technology, were downloaded from the Developmental Therapeutics Program (DTP) web server at http://www. dtp.nci.nih.gov. This data set contains 12626 mRNA expression profiles and is publicly available. The data set is first filtered to include only measurements that exhibited the strongest intensity in signal (Po0.05). The logarithm of each signal is taken to suppress extreme data values. Replicate measurements for each gene are then averaged by taking the median. Finally, only gene expression profiles having data available for at least 40 cell lines are included. This yielded a data set of 4923 genes to be included in our analysis.
Pathway Data
Three databases are used for pathway gene analysis: Kyoto Encyclopedia of Genes and Genomes (KEGG, http:// www.genome.ad.jp/kegg/), GO (http://www.geneontology.org/), and BioCarta (http://www.biocarta.com/). Annotations for 134 human pathways containing 2804 genes are downloaded from the KEGG ftp site (ftp://ftp.genome.ad.jp/ pub/kegg/pathways/hsa/). BioCarta annotations for 314 pathways containing 1406 human genes are downloaded from NCI's Cancer Genome Anatomy Project (CGAP, http:// cgap.nci.nih.gov/) ftp site (ftp://ftp1.nci.nih.gov/pub/ CGAP). Annotations for 3564 GO terms containing 10 921 human genes are downloaded from the GO ftp site (ftp:// ftp.geneontology.org/pub/go/). Within our gene expression data set, 1047 genes are present in KEGG, 604 are present in BioCarta, and 3210 are present in GO.
Pathway-GI 50 SOM Clade Correlations and Significance Calculation Gene-GI 50 SOM clade correlation scores A clade correlation coefficient between a gene and a GI 50 SOM clade is generated by first calculating the Pearson correlation coefficient r, between the gene expression data vector x and each node vector y in the clade. A data vector is composed of data values, either expression levels of a gene or GI 50 values of a drug, measured across all cell lines. Therefore, the number of cell lines determines the dimension of a data vector. The SOM algorithm identifies node (cluster) vectors by minimizing the deviation between the GI 50 data vectors and the node vectors. Here we choose to use node vectors in place of individual drug data vectors, because the drugs clustered in the same node share similar GI 50 profiles; thus, the node vector can be used as a representative of the drug profiles within the node. A node vector has the same dimension as a GI 50 data vector. The Pearson correlation coefficient is defined by r ¼ 
Pathway-GI 50 SOM clade correlation scores
For each pathway and each SOM clade, the clade correlation coefficients of all genes in the pathway and the genes that are not in the pathway are compared as two sample populations using the Kruskal-Wallis rank sum procedure and a H statistic (H-score) is generated:
where R t is the rank sum of sample population t, n t is the size of sample population t, k is the number of sample populations being compared, and
when each of the k sample populations being compared includes at least five observations, the sampling distribution of H is a very close approximation of the w 2 distribution for kÀ1 degrees of freedom. The H statistic closely approximates the w 2 statistic even when one or more of the samples includes as few as three observations. In the present study, only pathways that have at least three gene expression data vectors available are included in the calculations. The significance level (P-value) is assigned using the w 2 -distribution with one degree of freedom. A large H (H43.84) indicates a statistically significant difference (Po0.05) between the two sample populations. A negative sign is added to the H-score if the sum of ranks of the pathway clade-gene correlation coefficients is smaller than the nonpathway clade-gene correlation coefficients, that is, the GI 50 clade correlates stronger with nonpathway genes than pathway genes. A pathway is considered significantly correlated with a GI 50 clade if the H-score is 43.84 and Po0.05.
Randomization procedures are also employed to check the probability of getting a large positive H-score by chance as compared to the P-values obtained directly from the w 2 -distribution. Genes are selected and assigned randomly to build random pathways of sizes from 15 to 100, which is the typical size range of the real pathways that we have investigated, and the H-scores of each random pathway with all GI 50 SOM clades are calculated. This procedure is repeated 1000 times and the probabilities of getting H-scores at various levels are assessed. Further increase in the number of randomizations does not appear to affect the outcome. The probabilities obtained this way closely approximate (the log P vs log P(w 2 ) plot fits to a straight line with B0 intercept and slope of B1, R 2 ¼ 0.99), the P-values derived directly from the w 2 -distribution, that is, an H-score of 43.84, is required to get Po0.05. The H-scores required to reach a certain significance level (eg, Po0.05) appear to be independent of pathway size, that is, sample size. Therefore, Pvalues obtained from the w 2 -distribution are used directly as the significance measure with no further correction.
